Emmanuel “Chip” Walter Jr.
Professor of Pediatrics
Affiliate, Duke Global Health Institute
Contact
walte002@mc.duke.edu(919) 620-5346
Duke Vaccine and Trials Unit-RTP, Duke University PO Box 106008, Durham, NC 27710-6008
View WebsiteAppointment:
Topics:
Countries:
Emmanuel “Chip” Walter Jr.
Professor of Pediatrics
Affiliate, Duke Global Health Institute
Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.
Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies. He is the Duke Co-Principal Investigator for the NIAID Vaccine and Treatment Evaluation Unit (VTEU) which conducts clinical trials of vaccines and treatments for infectious diseases. He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for a CDC-funded project to further understand and reduce disparities in vaccine coverage among rural adolescents.
Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine coverage, prevention and treatment of infectious diseases.
Publications
-
El Sahly HM, Anderson EJ, Jackson LA, Neuzil KM, Atmar RL, Bernstein DI, et al. Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens. Vaccine. 2025 Jan 4;47:126689.Boutzoukas AE, Balevic SJ, Hemmersbach-Miller M, Winokur PL, Gu K, Chan AW, et al. Population Pharmacokinetics of Meropenem Across the Adult Lifespan. Clin Pharmacokinet. 2024 Dec 16;Walter EB, Schlaudecker EP, Talaat KR, Rountree W, Broder KR, Duffy J, et al. Safety of Simultaneous vs Sequential mRNA COVID-19 and Inactivated Influenza Vaccines: A Randomized Clinical Trial. JAMA Netw Open. 2024 Nov 4;7(11):e2443166.Schmader KE, Walter EB, Talaat KR, Rountree W, Poniewierski M, Randolph E, et al. Safety of Simultaneous Vaccination With Adjuvanted Zoster Vaccine and Adjuvanted Influenza Vaccine: A Randomized Clinical Trial. JAMA Netw Open. 2024 Oct 1;7(10):e2440817.
See more publications at Scholars@Duke